Supreme Court asks why drug margin caps cannot cover all medicines
By United One News · AI-generated summary of 5 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
The Supreme Court asked why the government capped trade margins for anti‑cancer drugs at 30% of MRP but did not extend the same limits to other medicines.
- The Court described the Centre’s explanation as “hardly anything to be happy about.”
- It highlighted steep markups on medical products as a concern.
- The Court sought clarification on why other medicines are not covered by the margin cap.
Covered by 5 outlets across the spectrum: 60% left, 40% center, 0% right.
How each side framed it
Left-leaning: CENTER: The coverage focuses on the Court’s criticism of the government’s selective pricing policy and its impact on drug affordability. (AI-generated summary of how this side framed it)
‘Rs 11 saline drip sold for Rs 270’: SC asks govt why it capped only cancer drugs
Supreme Court asks why drug margin caps cannot cover all medicines
Right-leaning outlets have under-covered this story. Of 5 outlets, only 0 are on the right of the spectrum.
Timeline
First reported by The Hindu BusinessLine on ; 5 articles from 5 outlets so far.
Who is covering this story
- Left-leaning (3): The New Indian Express, The Federal, The Hindu
- Center (2): The Hindu BusinessLine, Deccan Herald
Sources
- Supreme Court asks why drug margin caps cannot cover all medicines — The Hindu BusinessLine (center) ·
- SC questions why 3 per cent trade margin cap on anti-cancer drugs cannot cover all medicines — The New Indian Express (left-leaning) ·
- Centre caps trade margin of anti-cancer drugs at 30%, SC asks why not other medicines — Deccan Herald (center) ·
- ‘Rs 11 saline drip sold for Rs 270’: SC asks govt why it capped only cancer drugs — The Federal (left-leaning) ·
- Supreme Court wants cap on trade margin for all essential medicines and medical products — The Hindu (left-leaning) ·